Does this 62-year-old male smoker and drinker with a 5.6 cm hepatocellular carcinoma in the right hepatic lobe and portal vein thrombosis need referral to oncology?

Yes, this patient absolutely requires urgent referral to oncology and multidisciplinary team evaluation.

This 62-year-old male with confirmed hepatocellular carcinoma (LR-5.6 cm) and portal vein tumor thrombosis represents advanced-stage disease (BCLC Stage C) that mandates immediate multidisciplinary oncology assessment for treatment planning. 1

Why Immediate Referral is Critical

Disease Severity Assessment

This patient has multiple high-risk features that define advanced HCC:

• Confirmed HCC (LR-5): The 5.6 cm mass with arterial enhancement, washout, and pseudocapsule is diagnostic of hepatocellular carcinoma
• Portal vein tumor thrombosis (PVTT): Complete thrombosis of the right portal vein with possible tumor thrombus is one of the most ominous complications of HCC, occurring in 10-60% of patients 2
• Portal hypertension: Splenomegaly and collateral vessels indicate advanced liver disease
• Additional indeterminate lesion: The 3.1 cm LR-3 lesion requires surveillance but adds to tumor burden

Prognostic Implications Without Treatment

Untreated HCC with PVTT carries a median survival of only 2.7 months 2. The presence of PVTT indicates:

• Aggressive tumor biology
• High risk of intravascular spread and metastasis
• Worsening liver function
• Higher incidence of portal hypertension complications
• Extremely poor prognosis without intervention 3, 4

What the Multidisciplinary Team Will Provide

Guideline-Mandated Approach

Both the 2025 EASL and 2024 British Society of Gastroenterology guidelines explicitly state that patients should be discussed in multidisciplinary team meetings which provide access to the full range of treatment options for HCC 1, 5. This is not optional—it is a strong recommendation based on the complexity of managing both the cancer and underlying liver disease.

Treatment Options That Require Oncology Expertise

First-line systemic therapy options that the oncology team will evaluate include:

1. Atezolizumab plus bevacizumab: Currently the standard of care for advanced HCC, superior to sorafenib 5

   • Caveat: Requires assessment for variceal bleeding risk given portal hypertension

2. Alternative systemic therapies if immunotherapy contraindicated:

   • Lenvatinib (non-inferior to sorafenib) 5
   • Sorafenib (historical standard)
   • Durvalumab or tislelizumab as single agents 5

Locoregional therapies that may be combined with systemic treatment:

• Transarterial chemoembolization (TACE) combined with sorafenib shows improved survival compared to sorafenib alone in PVTT patients 2, 6
• Radiotherapy: Can prevent Vp3 progression to Vp4 PVTT and may improve outcomes 2, 7
• Hepatic arterial infusion chemotherapy (HAIC): Beneficial in selected PVTT cases 2

Surgical Evaluation

While PVTT traditionally precluded surgery, advances in surgical techniques have made resection possible in highly selected cases, potentially achieving cure with appropriate patient selection 3. The multidisciplinary team will determine if this patient could benefit from:

• Surgical resection with thrombectomy
• Potential for downstaging to curative therapy
• Liver transplantation consideration (though PVTT typically excludes this)

Critical Pitfalls to Avoid

1. Delaying referral: Every week matters when median survival without treatment is 2.7 months
2. Assuming nothing can be done: Modern combination therapies have dramatically improved outcomes compared to historical sorafenib monotherapy
3. Treating in isolation: The coexistence of cirrhosis, portal hypertension, and cancer requires coordinated hepatology-oncology management
4. Missing the window for intervention: Some patients can be downstaged to curative therapy, but only with prompt, aggressive treatment

Additional Concurrent Needs

Palliative Care Integration

All patients with advanced stage HCC should have early referral to palliative care services, alongside any active treatment 5. This is a strong recommendation with high-quality evidence. Palliative care should address:

• Physical symptoms related to both cancer and liver disease
• Psychological, social, and emotional needs
• Goals of care discussions
• Prognosis information at multiple timepoints

Hepatology Co-Management

The patient requires concurrent hepatology input for:

• Assessment of liver function (Child-Pugh score, MELD)
• Management of portal hypertension and variceal bleeding risk
• Evaluation for underlying cirrhosis etiology (alcohol use noted)
• Monitoring for hepatic decompensation during treatment

Follow-up of Indeterminate Lesion

The LR-3 lesion requires MRI follow-up in 3-6 months as recommended in the radiology report, though this is secondary to addressing the confirmed HCC with PVTT.

The combination of confirmed HCC, portal vein tumor involvement, and evidence of portal hypertension in a patient with risk factors (smoking, alcohol) creates an urgent oncologic emergency requiring immediate multidisciplinary evaluation to maximize survival and quality of life.